ReviewVirulence2017
The global epidemiology of carbapenemase-producing Enterobacteriaceae.
Review in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 508 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis
Intervention in the CPE Surveillance Algorithm and Isolation Re-evaluation With the Addition of PCR vs. Culture-based Protocol: Real-life Time Differences
Who cites it
508 citing papers in PubMed, 943 citations in OpenAlex.
- Carbapenem-resistant Enterobacterales (CRE) acquisition and molecular characterization following colistin monotherapy and colistin-meropenem combination therapy: findings from the AIDA randomized trial.Antimicrobial resistance and infection control · 2025Trial
- Prolonged fever in ESBL-producingRadiology case reports · 2026Article
- Genomic characterization ofOne health (Amsterdam, Netherlands) · 2026Article
- Infection outbreaks caused by carbapenemase-producing Enterobacterales: An epidemiological surveillance study in public hospitals in Chile, 2017-2024.Global epidemiology · 2026Article
- Article
- A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings.Science advances · 2026Article
- PlasmidRiskNet: An explainable machine-learning framework for antimicrobial resistance plasmid risk stratification.New microbes and new infections · 2026Article
- Convergence of Plasmid-Mediated tmexCD-toprJ With Critical Resistance Genes Fuels Spread of Multidrug Resistant Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Head-to-head in vitro susceptibility comparison of temocillin with amoxicillin/clavulanate, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Molecular Characterization and In Silico Functional Insights into Carbapenem Resistance in ClinicalPathogens (Basel, Switzerland) · 2026Article
- Carbapenemase type-dependent pharmacodynamic activity of minocycline-biapenem combination against carbapenemase-producingJAC-antimicrobial resistance · 2026Article
- Exploiting autophagy-targeting natural compounds for potential antimicrobial actions.Autophagy · 2026Review
- Impact of third-generation cephalosporin and carbapenem resistance profiles on the mortality of patients withJAC-antimicrobial resistance · 2026Article
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Diversity and Antimicrobial Resistance Profiles of ESBL-ProducingPathogens (Basel, Switzerland) · 2026Article
- Four-year antibiogram analysis of priority pathogens: guiding empirical therapy and monitoring resistance trends.Microbiology spectrum · 2026Observational
- Standardized numbering and alignment of the KPC family of β-lactamases.Antimicrobial agents and chemotherapy · 2026Article
- Prevalence of carbapenemase production among Enterobacterales with reduced susceptibility to meropenem in patients at Hospital de Clínicas de Porto Alegre (HCPA) between 2019 and 2024.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Multidrug-resistant enterobacterales carrying the acc(6')-Ian gene.Revista peruana de medicina experimental y salud publica · 2026Article
448 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Carbapenemase-producing Enterobacteriaceae (CPE) are an important and increasing threat to global health. Both clonal spread and plasmid-mediated transmission contribute to the ongoing rise in incidence of these bacteria. Among the 4 classes of β-lactamases defined by the Ambler classification system, the carbapenemases that confer carbapenem resistance in Enterobacteriaceae belong to 3 of them: Class A (K. pneumoniae carbapenemases, KPC), Class B (metallo-β-lactamases, MBL including New Delhi metallo-β-lactamases, NDM) and Class D (OXA-48-like carbapenemases). KPC-producing CPE are the most commonly occurring CPE in the United States. MBL-producing CPE have been most commonly associated with the Indian Subcontinent as well as with specific countries in Europe, including Romania, Denmark, Spain, and Hungary. The epicenter of OXA-48-like-producing is in Turkey and surrounding countries. Detailed knowledge of the epidemiology and molecular characteristics of CPE is essential to stem the spread of these pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.